Ardelyx, Inc.

ARDX Healthcare Biotechnology

Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

3.09 0.18 −5.50%
Market cap
$814.9M
P/E
0.0×
Fwd P/E
−122×
Dividend yield
—
F-score
2/9
Altman Z
1.12
Beneish M
−2.40
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 2 3 4
ROE
(36.18%) (36.21%) (39.46%) (38.61%)
ROA
(13.24%) (13.14%) (12.69%) (10.68%)
ROIC
(20.86%) (24.37%) (20.50%) (18.62%)
Return on Tangible Assets
(19.73%) (20.82%) (21.17%) (17.88%)
Average Days of Receivables
70.22 64.38 70.70 81.24
Free Cash Flow per Share
(0.23) (0.18) (0.15) (0.07)
Free Cash Flow
(55.35) (43.97) (37.50) (17.92)
Other line items

Show all line items

Columns are period end dates